Werewolf Therapeutics reports Q2 EPS (43c), consensus (38c)

Reports Q2 revenue $1.143M, consensus $840k. “We believe the data recently presented from our WTX-124 and WTX-330 clinical programs displays the meaningful impact we can have on patients through our INDUKINE(TM) approach, and we are well positioned to advance both programs towards key inflection points in the coming quarters,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf. “We continue to focus on enrollment in these two clinical trials and look forward to providing additional clinical data updates as we look to address the unmet medical needs for cancer patients with late-stage disease.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue